Book chapter
Interferon Alpha for the Treatment of Superficial Bladder Cancer
Advances in Bladder Research, pp.371-386
Advances in Experimental Medicine and Biology, Springer US
1999
DOI: 10.1007/978-1-4615-4737-2_29
PMID: 10599440
Abstract
The main problems that the patient with superficial transitional cell carcinoma (TCC) faces are the lifelong risk of tumor recurrence, and the risk of tumor progression and death secondary to cancer. Historically, cystectomy was the primary and only availible treatment option for patients who had recurrent bladder cancer or carcinoma in situ (CIS). However, the development of topical (intravesical) therapies for transitional cell carcinoma of the bladder has revolutionized the management of both superficial papillary tumors, and of flat carcinoma in situ. Due to the discovery of intravesical agents that have biologic activity against superficial TCC of the bladder (such as Bacillus Calmette-Guerrin (BCG) and Mitomycin), the mortality rate from bladder cancer has decreased despite a concurrent increase in the incidence of this malignancy.1
Details
- Title: Subtitle
- Interferon Alpha for the Treatment of Superficial Bladder Cancer
- Creators
- John Naitoh - UCLA Medical CenterJohn Franklin - Montefiore Medical CenterMichael A. O’Donnell - Beth Isreal HospitalArie S. Belldegrun - Ronald Reagan UCLA Medical Center
- Resource Type
- Book chapter
- Publication Details
- Advances in Bladder Research, pp.371-386
- Publisher
- Springer US; Boston, MA
- Series
- Advances in Experimental Medicine and Biology
- DOI
- 10.1007/978-1-4615-4737-2_29
- PMID
- 10599440
- ISSN
- 0065-2598
- Language
- English
- Date published
- 1999
- Academic Unit
- Urology
- Record Identifier
- 9984320850702771
Metrics
18 Record Views